NASDAQ:ONC BeOne Medicines Q1 2025 Earnings Results & Report $420.66 +0.68 (+0.16%) As of 11:08 AM Eastern This is a fair market value price provided by Massive. Learn more. BeOne Medicines beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released May 7, 2025. The company reported EPS of $1.22 versus the -$0.71 consensus estimate, while revenue of $1.12 billion fell short of the $1.12 billion estimate by $7.30 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 7, 2025TimeBefore Market Opens BeOne Medicines EPS ResultsActual EPS$1.22Consensus EPS -$0.71Beat/MissBeat by +$1.93One Year Ago EPSN/AEPS Beat Rate4 of last 6 quartersBeOne Medicines Revenue ResultsActual Revenue$1.12 billionExpected Revenue$1.12 billionBeat/MissMissed by -$7.30 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile BeOne Medicines Q1 2025 Earnings FAQ Did BeOne Medicines beat earnings estimates for Q1 2025? BeOne Medicines (NASDAQ:ONC) reported earnings of $1.22 per share for Q1 2025, beating the consensus estimate of -$0.71. The report was announced on Wednesday, May 7, 2025. What was BeOne Medicines' revenue for Q1 2025? BeOne Medicines reported revenue of $1.12 billion for Q1 2025, against a consensus estimate of $1.12 billion. BeOne Medicines Earnings HeadlinesUBS Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)November 10 at 1:25 AM | theglobeandmail.comBeOne Medicines AG 2026 Q3 - Results - Earnings Call PresentationNovember 9 at 6:44 PM | seekingalpha.comTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they did. Before a single vote was counted, the IMF flagged markets as increasingly exposed to a sharp correction, Ray Dalio called conditions a classic bubble, and Peter Schiff said a downturn could hit regardless of the outcome.November 12 at 1:00 AM | USA Capital Gold (Ad)CLSA Adjusts BeOne Medicines' Price Target to HK$336.80November 8, 2026 | marketscreener.comMBeOne Medicines (NASDAQ:ONC) Reaches New 1-Year High Following Better-Than-Expected EarningsNovember 7, 2026 | americanbankingnews.comBeOne Medicines (ONC) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | finance.yahoo.comSee More BeOne Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email. Email Address About BeOne MedicinesBeOne Medicines (NASDAQ:ONC), formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer. BeOne also develops additional oncology treatments through a broad research and clinical development pipeline. Co-founder John V. Oyler serves as the company’s chairman and chief executive officer.View BeOne Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
